23andMe Holding Co. (ME)
USD 0.61
(0.0%)
USD 0.61
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 206.64 Million USD | -9.63% |
| 2022 | 228.65 Million USD | -3.28% |
| 2021 | 236.41 Million USD | -77.44% |
| 2020 | 1.04 Billion USD | 287.43% |
| 2019 | 270.43 Million USD | -29.37% |
| 2018 | 382.88 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 224.54 Million USD | 8.66% |
| 2023 Q2 | 175.97 Million USD | -10.08% |
| 2023 Q1 | 195.7 Million USD | -14.41% |
| 2023 FY | 206.64 Million USD | -9.63% |
| 2023 Q3 | 231.02 Million USD | 31.28% |
| 2023 Q4 | 206.64 Million USD | -10.55% |
| 2022 Q1 | 208.03 Million USD | -12.0% |
| 2022 Q3 | 273.66 Million USD | 23.6% |
| 2022 Q4 | 228.65 Million USD | -16.44% |
| 2022 FY | 228.65 Million USD | -3.28% |
| 2022 Q2 | 221.41 Million USD | 6.43% |
| 2021 Q1 | 284.47 Million USD | -72.85% |
| 2021 FY | 236.41 Million USD | -77.44% |
| 2021 Q4 | 236.41 Million USD | -10.84% |
| 2021 Q3 | 265.14 Million USD | 8.87% |
| 2021 Q2 | 243.52 Million USD | -14.39% |
| 2020 Q4 | 1.04 Billion USD | 226.84% |
| 2020 Q2 | - USD | 0.0% |
| 2020 FY | 1.04 Billion USD | 287.43% |
| 2020 Q3 | 320.56 Million USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2019 FY | 270.43 Million USD | -29.37% |
| 2018 FY | 382.88 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -413.715% |
| Applied DNA Sciences, Inc. | 8.77 Million USD | -2253.834% |
| Aspira Women's Health Inc. | 8.62 Million USD | -2295.352% |
| Biodesix, Inc. | 94.51 Million USD | -118.637% |
| BioNexus Gene Lab Corp. | 1.74 Million USD | -11763.031% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -6038.704% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -6038.704% |
| Bionano Genomics, Inc. | 118.24 Million USD | -74.759% |
| CareDx, Inc | 223.28 Million USD | 7.452% |
| Check-Cap Ltd. | 1.33 Million USD | -15437.368% |
| Castle Biosciences, Inc. | 86.54 Million USD | -138.782% |
| DarioHealth Corp. | 38.24 Million USD | -440.324% |
| Exact Sciences Corporation | 3.32 Billion USD | 93.787% |
| Fulgent Genetics, Inc. | 139.82 Million USD | -47.792% |
| Guardant Health, Inc. | 1.62 Billion USD | 87.305% |
| ICON Public Limited Company | 7.74 Billion USD | 97.333% |
| IDEXX Laboratories, Inc. | 1.77 Billion USD | 88.361% |
| Illumina, Inc. | 4.36 Billion USD | 95.267% |
| Intelligent Bio Solutions Inc. | 5.59 Million USD | -3592.979% |
| iSpecimen Inc. | 6.07 Million USD | -3299.884% |
| Standard BioTools Inc. | 159.86 Million USD | -29.263% |
| MDxHealth SA | 121.92 Million USD | -69.488% |
| Medpace Holdings, Inc. | 1.09 Billion USD | 81.178% |
| Myriad Genetics, Inc. | 312.9 Million USD | 33.957% |
| Mainz Biomed B.V. | 12.15 Million USD | -1599.427% |
| ENDRA Life Sciences Inc. | 1.09 Million USD | -18769.167% |
| NeoGenomics, Inc. | 739.69 Million USD | 72.063% |
| Neogen Corporation | 1.44 Billion USD | 85.65% |
| Inotiv, Inc. | 588.04 Million USD | 64.858% |
| Natera, Inc. | 691.79 Million USD | 70.129% |
| OPKO Health, Inc. | 622.47 Million USD | 66.803% |
| Psychemedics Corporation | 6.59 Million USD | -3031.964% |
| Prenetics Global Limited | 44.01 Million USD | -369.511% |
| Prenetics Global Limited | 44.01 Million USD | -369.511% |
| Precipio, Inc. | 3.67 Million USD | -5527.642% |
| Personalis, Inc. | 95.65 Million USD | -116.027% |
| RadNet, Inc. | 2.07 Billion USD | 90.033% |
| Sera Prognostics, Inc. | 25.28 Million USD | -717.336% |
| Sotera Health Company | 2.68 Billion USD | 92.308% |
| Neuronetics, Inc. | 81.64 Million USD | -153.117% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -853.389% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -853.389% |
| Trinity Biotech plc | 83.38 Million USD | -147.826% |
| Twist Bioscience Corporation | 152.97 Million USD | -35.089% |
| Exagen Inc. | 34.25 Million USD | -503.349% |